{"protocolSection": {"identificationModule": {"nctId": "NCT00666536", "orgStudyIdInfo": {"id": "CVAA489AUS02"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy", "officialTitle": "A Multicenter, Randomized, Double Blind, Parallel Design Trial to Evaluate the Blood Pressure Lowering Efficacy Comparing Moderate Versus Aggressive Treatment Regimen of Valsartan + Amlodipine in Patients Uncontrolled on ARB Monotherapy", "acronym": "EXTRA"}, "statusModule": {"statusVerifiedDate": "2011-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-03"}, "primaryCompletionDateStruct": {"date": "2009-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-04-23", "studyFirstSubmitQcDate": "2008-04-24", "studyFirstPostDateStruct": {"date": "2008-04-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-11-16", "resultsFirstSubmitQcDate": "2010-11-17", "resultsFirstPostDateStruct": {"date": "2010-12-10", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-09-20", "lastUpdatePostDateStruct": {"date": "2016-10-27", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Novartis", "oldOrganization": "pharmaceuticals"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this trial is to compare blood pressure lowering efficacy of moderate Valsartan + Amlodipine treatment regimen (160 / 5 mg) with that of aggressive regimen (320 / 10 mg) in patients uncontrolled on ARB monotherapy, other than Valsartan"}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Hypertension", "adults", "Valsartan + Amlodipine", "Angiotensin Receptor Blockers"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 728, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Aggressive treatment regimen (5/320 mg to 10/320 mg)", "type": "ACTIVE_COMPARATOR", "description": "Valsartan + Amlodipine, daily: 320 mg + 5 mg (2 weeks); Valsartan + Amlodipine, daily: 320 mg + 10 mg (2 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)", "interventionNames": ["Drug: valsartan and amlodipine"]}, {"label": "Moderate treatment regimen (5/160 mg)", "type": "ACTIVE_COMPARATOR", "description": "Valsartan + Amlodipine, daily dose: 160 mg + 5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)", "interventionNames": ["Drug: valsartan and amlodipine"]}], "interventions": [{"type": "DRUG", "name": "valsartan and amlodipine", "armGroupLabels": ["Aggressive treatment regimen (5/320 mg to 10/320 mg)"]}, {"type": "DRUG", "name": "valsartan and amlodipine", "armGroupLabels": ["Moderate treatment regimen (5/160 mg)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline to Week 4 in Mean Sitting Systolic Blood Pressure (MSSBP)", "timeFrame": "Baseline and Week 4"}], "secondaryOutcomes": [{"measure": "Percentage of Patients Achieving the Blood Pressure (BP) Goal of < 140/90 mmHg at Weeks 2,4,8 and 12", "timeFrame": "Weeks 2, 4, 8 and 12"}, {"measure": "Change From Baseline to Week 4 in Mean Sitting Diastolic Blood Pressure (MSDBP)", "timeFrame": "Baseline and Week 4"}, {"measure": "Change From Baseline to Weeks 2, 8 and 12 in MSSBP", "timeFrame": "Baseline and Weeks 2, 8 and 12"}, {"measure": "Change From Baseline to Weeks 2, 8 and 12 in MSDBP", "timeFrame": "Baseline and Weeks 2, 8 and 12"}, {"measure": "Percentage of Patients Achieving BP Goal of MSSBP < 140mmHg at Weeks 2, 4, 8 and 12", "timeFrame": "Weeks 2, 4, 8 and 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female outpatients\n* 18 Years of age or older\n* Mean Sitting Systolic Blood Pressure (the top number) greater than or equal to 150 mmHg and lower than 200 mmHg while on Angiotensin-Receptor Blocker monotherapy for a minimum period of 28 days prior to randomization\n\nExclusion Criteria:\n\n* Mean Sitting Systolic Blood Pressure (the top number) greater than or equal to 200 mmHg and/or Mean Sitting Diastolic Blood Pressure greater than or equal to 120 mmHg\n* Transient ischemic attack (mini-stroke), myocardial infarction (heart attack), all types of revascularization procedures in the last 6 months\n* Treatment with valsartan or any combination antihypertensive treatment with 28 days prior to screening (Visit 1)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Suzanne Oparil, MD et al", "affiliation": "University of Alabama at Birmingham", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Egan Healthcare", "city": "Metairie", "state": "Louisiana", "zip": "70002", "country": "United States", "geoPoint": {"lat": 29.98409, "lon": -90.15285}}]}, "referencesModule": {"references": [{"pmid": "21045734", "type": "RESULT", "citation": "Oparil S, Giles T, Ofili EO, Pitt B, Seifu Y, Hilkert R, Samuel R, Sowers JR. Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. J Hypertens. 2011 Jan;29(1):161-70. doi: 10.1097/HJH.0b013e32834000a7."}, {"pmid": "21386706", "type": "DERIVED", "citation": "Giles TD, Oparil S, Ofili EO, Pitt B, Purkayastha D, Hilkert R, Samuel R, Sowers JR. The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. Blood Press Monit. 2011 Apr;16(2):87-95. doi: 10.1097/MBP.0b013e328344c713."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "369 and 359 are the total randomized patients by treatment groups respectively. In the baseline measures tables 366 and 357 are the total patients for the ITT population by treatment group.", "groups": [{"id": "FG000", "title": "Aggressive Treatment Regimen (5/320 mg to 10/320 mg)", "description": "Valsartan + Amlodipine, daily: 320 mg + 5 mg (2 weeks); Valsartan + Amlodipine, daily: 320 mg + 10 mg (2 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)"}, {"id": "FG001", "title": "Moderate Treatment Regimen (5/160 mg)", "description": "Valsartan + Amlodipine, daily dose: 160 mg + 5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "369"}, {"groupId": "FG001", "numSubjects": "359"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "336"}, {"groupId": "FG001", "numSubjects": "322"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "33"}, {"groupId": "FG001", "numSubjects": "37"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "19"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Protocol deviation(s)", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Aggressive Treatment Regimen (5/320 mg to 10/320 mg)", "description": "Valsartan + Amlodipine, daily: 320 mg + 5 mg (2 weeks); Valsartan + Amlodipine, daily: 320 mg + 10 mg (2 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)"}, {"id": "BG001", "title": "Moderate Treatment Regimen (5/160 mg)", "description": "Valsartan + Amlodipine, daily dose: 160 mg + 5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "366"}, {"groupId": "BG001", "value": "357"}, {"groupId": "BG002", "value": "723"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "< 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "302"}, {"groupId": "BG001", "value": "292"}, {"groupId": "BG002", "value": "594"}]}]}, {"title": ">=65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "64"}, {"groupId": "BG001", "value": "65"}, {"groupId": "BG002", "value": "129"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.4", "spread": "10.98"}, {"groupId": "BG001", "value": "55.0", "spread": "10.98"}, {"groupId": "BG002", "value": "54.7", "spread": "10.98"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "157"}, {"groupId": "BG001", "value": "157"}, {"groupId": "BG002", "value": "314"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "200"}, {"groupId": "BG002", "value": "409"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline to Week 4 in Mean Sitting Systolic Blood Pressure (MSSBP)", "populationDescription": "Intent to treat (ITT), Last observation carried forward (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "Aggressive Treatment Regimen (5/320 mg to 10/320 mg)", "description": "Valsartan + Amlodipine, daily: 320 mg + 5 mg (2 weeks); Valsartan + Amlodipine, daily: 320 mg + 10 mg (2 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)"}, {"id": "OG001", "title": "Moderate Treatment Regimen (5/160 mg)", "description": "Valsartan + Amlodipine, daily dose: 160 mg + 5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "366"}, {"groupId": "OG001", "value": "357"}]}], "classes": [{"title": "Baseline MSSBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "163.9", "spread": "11.85"}, {"groupId": "OG001", "value": "163.3", "spread": "11.40"}]}]}, {"title": "Week 4 MSSBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "140.9", "spread": "14.61"}, {"groupId": "OG001", "value": "144.4", "spread": "14.21"}]}]}, {"title": "Change From Baseline to Week 4 in MSSBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-23.0", "spread": "14.60"}, {"groupId": "OG001", "value": "-18.9", "spread": "13.92"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving the Blood Pressure (BP) Goal of < 140/90 mmHg at Weeks 2,4,8 and 12", "populationDescription": "Intent to treat (ITT), Last observation carried forward (LOCF)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Patients", "timeFrame": "Weeks 2, 4, 8 and 12", "groups": [{"id": "OG000", "title": "Aggressive Treatment Regimen (5/320 mg to 10/320 mg)", "description": "Valsartan + Amlodipine, daily: 320 mg + 5 mg (2 weeks); Valsartan + Amlodipine, daily: 320 mg + 10 mg (2 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)"}, {"id": "OG001", "title": "Moderate Treatment Regimen (5/160 mg)", "description": "Valsartan + Amlodipine, daily dose: 160 mg + 5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "366"}, {"groupId": "OG001", "value": "357"}]}], "classes": [{"title": "Week 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "25.1"}, {"groupId": "OG001", "value": "25.8"}]}]}, {"title": "Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "43.7"}, {"groupId": "OG001", "value": "31.1"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "61.7"}, {"groupId": "OG001", "value": "46.2"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "59.8"}, {"groupId": "OG001", "value": "50.7"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 4 in Mean Sitting Diastolic Blood Pressure (MSDBP)", "populationDescription": "Intent to treat (ITT), Last observation carried forward (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "Aggressive Treatment Regimen (5/320 mg to 10/320 mg)", "description": "Valsartan + Amlodipine, daily: 320 mg + 5 mg (2 weeks); Valsartan + Amlodipine, daily: 320 mg + 10 mg (2 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)"}, {"id": "OG001", "title": "Moderate Treatment Regimen (5/160 mg)", "description": "Valsartan + Amlodipine, daily dose: 160 mg + 5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "366"}, {"groupId": "OG001", "value": "357"}]}], "classes": [{"title": "Baseline MSDBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "95.5", "spread": "11.19"}, {"groupId": "OG001", "value": "95.0", "spread": "10.33"}]}]}, {"title": "Week 4 MSDBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "84.8", "spread": "11.47"}, {"groupId": "OG001", "value": "86.2", "spread": "9.6"}]}]}, {"title": "Change From Baseline to Week 4 in MSDBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.7", "spread": "9.39"}, {"groupId": "OG001", "value": "-8.8", "spread": "9.08"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Weeks 2, 8 and 12 in MSSBP", "populationDescription": "Intent to treat (ITT), Last observation carried forward (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Weeks 2, 8 and 12", "groups": [{"id": "OG000", "title": "Aggressive Treatment Regimen (5/320 mg to 10/320 mg)", "description": "Valsartan + Amlodipine, daily: 320 mg + 5 mg (2 weeks); Valsartan + Amlodipine, daily: 320 mg + 10 mg (2 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)"}, {"id": "OG001", "title": "Moderate Treatment Regimen (5/160 mg)", "description": "Valsartan + Amlodipine, daily dose: 160 mg + 5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "366"}, {"groupId": "OG001", "value": "357"}]}], "classes": [{"title": "Baseline MSSBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "163.9", "spread": "11.85"}, {"groupId": "OG001", "value": "163.3", "spread": "11.40"}]}]}, {"title": "Week 2 MSSBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "147.0", "spread": "14.93"}, {"groupId": "OG001", "value": "146.0", "spread": "14.80"}]}]}, {"title": "Change From Baseline to Week 2 in MSSBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-16.9", "spread": "13.94"}, {"groupId": "OG001", "value": "-17.3", "spread": "13.80"}]}]}, {"title": "Week 8 MSSBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "136.0", "spread": "15.27"}, {"groupId": "OG001", "value": "140.5", "spread": "15.91"}]}]}, {"title": "Change From Baseline to Week 8 in MSSBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-27.9", "spread": "16.08"}, {"groupId": "OG001", "value": "-22.8", "spread": "16.15"}]}]}, {"title": "Week 12 MSSBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "135.7", "spread": "14.97"}, {"groupId": "OG001", "value": "139.2", "spread": "15.63"}]}]}, {"title": "Change From Baseline to Week 12 in MSSBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-28.1", "spread": "16.59"}, {"groupId": "OG001", "value": "-24.1", "spread": "16.07"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Weeks 2, 8 and 12 in MSDBP", "populationDescription": "Intent to treat (ITT), Last observation carried forward (LOCF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Weeks 2, 8 and 12", "groups": [{"id": "OG000", "title": "Aggressive Treatment Regimen (5/320 mg to 10/320 mg)", "description": "Valsartan + Amlodipine, daily: 320 mg + 5 mg (2 weeks); Valsartan + Amlodipine, daily: 320 mg + 10 mg (2 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)"}, {"id": "OG001", "title": "Moderate Treatment Regimen (5/160 mg)", "description": "Valsartan + Amlodipine, daily dose: 160 mg + 5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "366"}, {"groupId": "OG001", "value": "357"}]}], "classes": [{"title": "Baseline MSDBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "95.5", "spread": "11.19"}, {"groupId": "OG001", "value": "95.0", "spread": "10.33"}]}]}, {"title": "Week 2 MSDBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "88.2", "spread": "10.93"}, {"groupId": "OG001", "value": "87.1", "spread": "10.38"}]}]}, {"title": "Change From Baseline to Week 2 in MSDBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.3", "spread": "8.51"}, {"groupId": "OG001", "value": "-7.9", "spread": "9.66"}]}]}, {"title": "Week 8 MSDBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "81.6", "spread": "11.15"}, {"groupId": "OG001", "value": "84.0", "spread": "11.39"}]}]}, {"title": "Change From Baseline to Week 8 in MSDBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.9", "spread": "9.97"}, {"groupId": "OG001", "value": "-11.0", "spread": "10.33"}]}]}, {"title": "Week 12 MSDBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "81.5", "spread": "10.62"}, {"groupId": "OG001", "value": "83.8", "spread": "10.61"}]}]}, {"title": "Change From Baseline to Week 12 in MSDBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.0", "spread": "10.41"}, {"groupId": "OG001", "value": "-11.2", "spread": "10.48"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving BP Goal of MSSBP < 140mmHg at Weeks 2, 4, 8 and 12", "populationDescription": "Intent to treat (ITT), Last observation carried forward (LOCF)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Patients", "timeFrame": "Weeks 2, 4, 8 and 12", "groups": [{"id": "OG000", "title": "Aggressive Treatment Regimen (5/320 mg to 10/320 mg)", "description": "Valsartan + Amlodipine, daily: 320 mg + 5 mg (2 weeks); Valsartan + Amlodipine, daily: 320 mg + 10 mg (2 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)"}, {"id": "OG001", "title": "Moderate Treatment Regimen (5/160 mg)", "description": "Valsartan + Amlodipine, daily dose: 160 mg + 5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "366"}, {"groupId": "OG001", "value": "357"}]}], "classes": [{"title": "Week 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "31.1"}, {"groupId": "OG001", "value": "32.5"}]}]}, {"title": "Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "49.2"}, {"groupId": "OG001", "value": "37.5"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "66.1"}, {"groupId": "OG001", "value": "49.6"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "62.8"}, {"groupId": "OG001", "value": "55.7"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "12 weeks", "eventGroups": [{"id": "EG000", "title": "Aggressive Treatment Regimen (5/320 mg to 10/320 mg)", "description": "Valsartan + Amlodipine, daily: 320 mg + 5 mg (2 weeks); Valsartan + Amlodipine, daily: 320 mg + 10 mg (2 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)", "seriousNumAffected": 4, "seriousNumAtRisk": 369, "otherNumAffected": 50, "otherNumAtRisk": 369}, {"id": "EG001", "title": "Moderate Treatment Regimen (5/160 mg)", "description": "Valsartan + Amlodipine, daily dose: 160 mg + 5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)", "seriousNumAffected": 10, "seriousNumAtRisk": 359, "otherNumAffected": 29, "otherNumAtRisk": 359}], "seriousEvents": [{"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 359}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 359}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 359}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 359}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 359}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 359}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 359}]}, {"term": "Small intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 359}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 359}]}, {"term": "Gait disturbance", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 359}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 359}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 359}]}, {"term": "Pneumonia bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 359}]}, {"term": "Electrocardiogram T wave abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 359}]}, {"term": "Diabetic ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 359}]}, {"term": "Type 1 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 359}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 359}]}, {"term": "Breast cancer in situ", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 359}]}, {"term": "Balance disorder", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 359}]}, {"term": "Hypoaesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 359}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 359}]}, {"term": "Suicide attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 359}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 359}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 359}]}, {"term": "Orthopnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 359}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 359}]}], "otherEvents": [{"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 32, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 359}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 369}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 359}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M3724", "name": "Aggression", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000068756", "term": "Valsartan"}, {"id": "D000068838", "term": "Amlodipine, Valsartan Drug Combination"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M9910", "name": "Hydrochlorothiazide", "relevance": "LOW"}, {"id": "M319", "name": "Amlodipine, Valsartan Drug Combination", "asFound": "Laser procedure", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}